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Women with a BRCA1 or BRCA2 mutation, who have a considerable 
increased risk of developing breast cancer, now face the choice of 
intensive screening, prophylactic surgery or chemoprevention. The 
efficacy of the various medical options and the durability of its effects 
are of major concern to female BRCA1/2 mutation carriers, and will 
influence their choices. Although prophylactic mastectomy reduces 
the rate of breast cancer risk by 90% or more, the intervention 
is irreversible, with potential harms that may be unacceptable for 
certain women. 
This thesis shows that intensive screening is an appropriate 
alternative to reduce the risk of breast cancer death for both BRCA1/2 
mutation carriers and for women with a clear family history of breast 
cancer where a mutation has not (yet) been found. Intensive screening 
is expected to lead to significant breast cancer mortality reductions 
with no adverse effect on short-term generic health-related quality 
of life and general distress. Including magnetic resonance imaging 
in BRCA1/2 mutation carriers (50-85% cumulative lifetime risk for 
developing breast cancer) surveillance is cost-effective. For moderate-
risk women (15-30% cumulative lifetime risk for developing breast 
cancer), intensive screening with only mammography, alternatively in 
combination with clinical breast examination, is most cost-effective.
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